Fakih M et al. POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC). ASCO 2025;Abstract 3525.
Garg A et al. Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035. J Natl Cancer Inst 2024;116(9):1508-12. Abstract
Kim S et al. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): A randomised, non-comparative, phase 2 study. Lancet Oncol 2024;25(4):518-28. Abstract
Marabelle A et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7(5):446-54. Abstract
Morris V et al. NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal. ESMO GI 2023;Abstract O-12.
Morris VK et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(4):446-53. Abstract
Rao S et al. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): A global, phase 3 randomised controlled trial. Lancet 2025;405(10495):2144-52. Abstract
Rao S et al. Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC). ESMO Immuno-Oncology Congress 2025;Abstract 123MO.
Rao S et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7(4). Abstract
Rao S et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 2020;38(22):2510-8. Abstract